Abstract:Background There is an increasing interest in using preclinical models for development and assessment of medical devices and imaging techniques for prostatic disease care. Still, a comprehensive assessment of the prostate's radiological anatomy in primary preclinical models such as dogs, rabbits, and mice utilizing human anatomy as a reference point remains necessary with no optimal model for each purpose being clearly defined in the literature. Therefore, this study compares the anatomical characteristics of different animal models to the human prostatic gland from the imaging perspective. Methods We imaged five Beagle laboratory dogs, five New Zealand White rabbits, and five mice, all sexually mature males, under Institutional Animal Care and Use Committee (IACUC) approval. Ultrasonography (US) was performed using the Vevo® F2 for mice (57 MHz probe). Rabbits and dogs were imaged using the Siemens® Acuson S3000 (17 MHz probe) and endocavitary (8 MHz) probes, respectively. Magnetic resonance imaging (MRI) was also conducted with a 7T scanner in mice and 3T scanner in rabbits and dogs. Results Canine transrectal US emerged as the optimal method for US imaging, depicting a morphologically similar gland to humans but lacking echoic zonal differentiation. MRI findings in canines indicated a homogeneously structured gland similar to the human peripheral zone on T2‐weighted images (T2W) and apparent diffusion coefficient (ADC). In rabbits, US imaging faced challenges due to the pubic symphysis, whereas MRI effectively visualized all structures with the prostate presenting a similar aspect to the human peripheral gland on T2W and ADC maps. Murine prostate assessment revealed poor visualization of the prostate glands in ultrasound due to its small size, while 7T MRI delineated the distinct prostates and its lobes, with the lateral and dorsal prostate resembling the peripheral zone and the anterior prostate the central zone of the human gland. Conclusion Dogs stand out as superior models for advanced preclinical studies in prostatic disease research. However, mice present as a good model for early stage studies and rabbits are a cost‐effective alternative and serve as valuable tools in specific research domains when canine research is not feasible.

An overview of the latest in state-of-the-art murine models for prostate cancer

Advances in Prostate Cancer Research Models: from Transgenic Mice to Tumor Xenografting Models

Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX

In Vivo Models for Prostate Cancer Research

Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation

An Overview of Current Alternative Models for Use in the Context of Prostate Cancer Research

Genetically defined mouse models that mimic natural aspects of human prostate cancer development.

Diverse Landscape of Genetically Engineered Mouse Models: Genomic and Molecular Insights into Prostate Cancer

An Emerging Precision Medicine Model for Prostate Cancer Research

Prostate cancer xenografts and hormone induced prostate carcinogenesis

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research

Orthotopic and metastatic tumour models in preclinical cancer research

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease

Colorectal cancer murine models: Initiation to metastasis

Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis

Research progress in the establishment of pancreatic cancer models and preclinical applications

In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer

Animal models for modeling pancreatic cancer and novel drug discovery

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors